Mkk7 Protects Against Cardiac Dysfunction in Heart Failure with Preserved Ejection Fraction

Tayyiba Azam; Hongyuan Zhang; Susanne Hille; Oliver J. Müller; Elizabeth J. Cartwright; Xin Wang

doi:10.53941/ijddp.2024.100002

Abstract

Shifts in epidemiological patterns foretell a rapid increase in the number of patients with heart failure (HF) globally, representing a significant health and economic burden. Heart failure with preserved ejection (HFpEF) is now considered the prevailing subtype of HF, with no effective treatment available to combat this syndrome. Previous studies have highlighted the cardioprotective role of MKK7 during cardiac pathology, however, no extensive research has been performed to examine MKK7 in the context of HFpEF. This study aimed to address this shortcoming by using adeno-associated virus (AAV) 9 to overexpress MKK7 in the two-hit clinically relevant HFpEF mouse model. We report that cardiomyocyte-specific overexpression of MKK7 improved the HFpEF phenotype in mice, by impeding cardiac diastolic dysfunction and myocardial fibrosis. Mechanistically, it was found that MKK7 ameliorated ER stress by maintaining IRE1-XBP1 signalling and blunted CHOP increase in the myocardium. To summarise, MKK7 overexpression holds the ability to protect the myocardium from HFpEF associated pathologies.

References

1.
Ziaeian, B.; Fonarow, G.C. Epidemiology and aetiology of heart failure. Nat. Rev. Cardiol. 2016, 13, 368‒378.
2.
Harper, A.R.; Patel, H.C.; Lyon, A.R. Heart failure with preserved ejection fraction. Clin. Med. 2018, 18, s24‒s29.
3.
Upadhya, B.; Haykowsky, M.J.; Kitzman, D.W. Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions. Heart Fail. Rev. 2018, 23, 609‒629.
4.
Kjeldsen, S.E.; von Lueder, T.G.; Smiseth, O.A.; et al. Medical Therapies for Heart Failure with Preserved Ejection Fraction. Hypertension 2020, 75, 23‒32.
5.
González-López, E.; Gallego-Delgado, M.; Guzzo-Merello, G. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur. Heart. J. 2015, 36, 2585‒2594.
6.
Schiattarella, G.G.; Altamirano, F.; Tong, D.; et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature 2019, 568, 351‒356.
7.
Hetz, C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell. Biol. 2012, 13, 89‒102.
8.
Azam, T.; Zhang, H.; Zhou, F.; et al. Recent Advances on Drug Development and Emerging Therapeutic Agents Through Targeting Cellular Homeostasis for Ageing and Cardiovascular Disease. Front. Aging 2022, 3, 888190.
9.
Morrison, D.K. MAP kinase pathways. Cold Spring Harb. Perspect. Biol. 2012, 4, a011254.
10.
Plotnikov, A.; Zehorai, E.; Procaccia, S.; et al. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim. Biophys. Acta 2011, 1813, 1619‒1633.
11.
Chowdhury, S.K.; Liu, W.; Zi, M.; et al. Stress-Activated Kinase Mitogen-Activated Kinase Kinase-7 Governs Epigenetics of Cardiac Repolarization for Arrhythmia Prevention. Circulation 2017, 135, 683‒699.
12.
Liu, W.; Zi, M.; Chi, H.; et al. Deprivation of MKK7 in cardiomyocytes provokes heart failure in mice when exposed to pressure overload. J. Mol. Cell. Cardiol. 2011, 50, 702‒711.
13.
Liang, Q.; Bueno, O.F.; Wilkins, B.J.; et al. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J. 2003, 22, 5079‒5089.
14.
Shao, Z.; Bhattacharya, K.; Hsich, E.; et al. c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo. Circ. Res. 2006, 98, 111‒118.
15.
Schiattarella, G.G.; Altamirano, F.; Kim, S.Y.; et al. Xbp1s-FoxO1 axis governs lipid accumulation and contractile performance in heart failure with preserved ejection fraction. Nat. Commun. 2021, 12, 1684.
16.
Chong, W.C.; Shastri, M.D.; Eri, R. Endoplasmic Reticulum Stress and Oxidative Stress: A Vicious Nexus Implicated in Bowel Disease Pathophysiology. Int. J. Mol. Sci. 2017, 18, 771. doi: 10.3390/ijms18040771.
17.
Liu, B.; Zhang, Z.; Hu, Y.; et al. Sustained ER stress promotes hyperglycemia by increasing glucagon action through the deubiquitinating enzyme USP14. Proc. Natl. Acad. Sci. 2019, 116, 21732‒21738.
18.
Fu, H.Y.; Okada, K.; Liao, Y.; et al. Ablation of C/EBP homologous protein attenuates endoplasmic reticulum-mediated apoptosis and cardiac dysfunction induced by pressure overload. Circulation 2010, 122, 361‒369.
19.
Miyazaki, Y.; Kaikita, K.; Endo, M.; et al. C/EBP homologous protein deficiency attenuates myocardial reperfusion injury by inhibiting myocardial apoptosis and inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1124‒1132.
20.
Suzuki, T.; Gao, J.; Ishigaki, Y.; et al. ER Stress Protein CHOP Mediates Insulin Resistance by Modulating Adipose Tissue Macrophage Polarity. Cell Rep. 2017, 18, 2045‒2057.
21.
Oyadomari, S.; Mori, M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004, 11, 381‒389.
22.
Ji, Y.; Zhao, Z.; Cai, T.; et al. Liraglutide alleviates diabetic cardiomyopathy by blocking CHOP-triggered apoptosis via the inhibition of the IRE-α pathway. Mol. Med. Rep. 2014, 9, 1254‒1258.
23.
Anker, S.D.; Butler, J.; Filippatos, G.; et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N. Engl. J. Med. 2021, 385, 1451‒1461.
24.
McMurray, J.J.V.; DeMets, D.L.; Inzucchi, S.E.; et al. DAPA-HF Committees and Investigators. The Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur. J. Heart Fail. 2019, 21, 1402‒1411.
25.
Neal, B.; Perkovic, V.; Matthews, D.R. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N. Engl. J. Med. 2017, 377, 2099.
26.
Tong, D.; Schiattarella, G.G.; Jiang, N.; et al. NAD+ Repletion Reverses Heart Failure with Preserved Ejection Fraction. Circ. Res. 2021, 128, 1629‒1641.
27.
Loffredo, F.S.; Nikolova, A.P.; Pancoast, J.R.; et al. Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. Circ. Res. 2014, 115, 97‒107.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us